The stock price of Hyderabad-based Aurobindo Pharma and Granules India Limited today appreciated by as much as 4.18 per cent and 3.43 per cent respectively on the Bombay Stock Exchange (BSE) in the light of the reports that their manufacturing units were inspected by the US FDA in connection with some new drug applications.
While Granules India has informed the stock exchanges that the US FDA had inspected one of its facility last week and the inspection concluded with no observations, rumours about a similar inspection with regard to Aurobindo also surfaced on Monday. However, an Aurobindo spokesperson did not respond to confirm or deny this development.
Granules said the inspection was triggered by one of its abbreviated new drug application (ANDA).
Aurobindo scrip was up by Rs 47.95 at Rs 1,194.65 while Granules India shares were Rs 30.10 higher than the previous close at Rs 908.70 on Monday.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.